アベマシクリブ (LY2835219) とフルベストラントとプラセボとフルベストラントの治療歴のある乳がんの比較 (postMONARCH)
postMONARCH: CDK4 および 6 阻害剤および内分泌で進行した HR+、HER2-、進行性または転移性乳がんの参加者を対象に、アベマシクリブ + フルベストラントとプラセボ + フルベストラントの有効性を比較する、無作為化、二重盲検、プラセボ対照、第 III 相試験治療
This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
アクセスの拡大
連絡先と場所
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85004
- St. Joseph's Hospital and Medical Center
-
-
Arkansas
-
Springdale、Arkansas、アメリカ、72762
- Highlands Oncology Group
-
-
California
-
Fullerton、California、アメリカ、92835
- Providence Medical Foundation
-
Los Alamitos、California、アメリカ、90720
- Cancer and Blood Specialty Clinic
-
Los Angeles、California、アメリカ、90033
- Keck School of Medicine of USC
-
Los Angeles、California、アメリカ、90024
- TRIO-US (Translational Research in Oncology-US)
-
Santa Monica、California、アメリカ、90404
- UCLA Hematology/Oncology - Parkside
-
Sylmar、California、アメリカ、91342
- Olive View-UCLA Medical Center
-
Torrance、California、アメリカ、90505
- Torrance Memorial Physician Network / Cancer Care
-
Whittier、California、アメリカ、90602
- PIH Health Hematology Medical Oncology
-
-
Colorado
-
Denver、Colorado、アメリカ、80220
- Rocky Mountain Cancer Center - Hale Parkway
-
-
Florida
-
Fort Myers、Florida、アメリカ、33901-8101
- Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
-
Hollywood、Florida、アメリカ、33024
- Millennium Oncology Research Clinic
-
Miami、Florida、アメリカ、33136
- University of Miami Hospital and Clinics, Sylvester Cancer Center
-
Pensacola、Florida、アメリカ、32503
- Woodlands Medical Specialists, PA
-
Sarasota、Florida、アメリカ、34232
- Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
-
West Palm Beach、Florida、アメリカ、33401
- Florida Cancer Specialists EAST/Sarah Cannon Research Institute/SCRI
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- Winship Cancer Institute, Emory University
-
Gainesville、Georgia、アメリカ、30501
- Northeast Georgia Medical Center
-
Macon、Georgia、アメリカ、31201
- Central Georgia Cancer Care
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96826
- Kapiolani Medical Center for Women and Children
-
-
Illinois
-
Harvey、Illinois、アメリカ、60426
- Ingalls Memorial Hospital
-
-
Louisiana
-
Baton Rouge、Louisiana、アメリカ、70809
- Hematology Oncology Clinic- Baton Rouge/Sarah Cannon Research Institute/SCRI
-
Lake Charles、Louisiana、アメリカ、70601
- Clinical Trials of SWLA
-
-
Maine
-
Lewiston、Maine、アメリカ、04240
- Central Maine Medical Center
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21237
- Mfsmc-Hjwci
-
Clinton、Maryland、アメリカ、20735
- Maryland Oncology Hematology, P.A. - Clinton
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- Massachusetts General Hospital
-
Boston、Massachusetts、アメリカ、02215
- Dana Farber Cancer Institute
-
Danvers、Massachusetts、アメリカ、01923
- MGH Northshore Cancer Center
-
Fairhaven、Massachusetts、アメリカ、02719
- Southcoast Centers for Cancer Care
-
Foxborough、Massachusetts、アメリカ、02035
- Dana-Farber Cancer Institute - Foxborough
-
Methuen、Massachusetts、アメリカ、01844
- Dana Farber Cancer Center Merrimack Valley
-
Milford、Massachusetts、アメリカ、01757
- Dana Farber Cancer Institute
-
Newton、Massachusetts、アメリカ、02462
- Mass General Cancer Center
-
South Weymouth、Massachusetts、アメリカ、02190
- Dana Farber Cancer Institute
-
Worcester、Massachusetts、アメリカ、01606
- Reliant Medical Group
-
-
Montana
-
Billings、Montana、アメリカ、59102
- St. Vincent Frontier Cancer Center
-
-
New Hampshire
-
Londonderry、New Hampshire、アメリカ、03053
- Dana Farber Cancer Center Londonderry
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87106
- University of New Mexico Comprehensive Cancer Center
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02906
- Lifespan Cancer Institute
-
-
Tennessee
-
Chattanooga、Tennessee、アメリカ、37404
- Tennessee Oncology-Chattanooga /Sarah Cannon Research Institute/SCRI
-
Nashville、Tennessee、アメリカ、37203
- Sarah Cannon Research Institute/SCRI
-
Nashville、Tennessee、アメリカ、37203
- Tennessee Oncology-Nashville/Sarah Cannon Research Institute/SCRI
-
-
Texas
-
Bedford、Texas、アメリカ、76022
- Texas Oncology - Bedford
-
Denton、Texas、アメリカ、76201
- Texas Oncology - Denton
-
El Paso、Texas、アメリカ、79902
- Texas Oncology, P.A.
-
Houston、Texas、アメリカ、77030-4009
- University of Texas MD Anderson Cancer Center
-
McKinney、Texas、アメリカ、75071
- Texas Oncology - McKinney
-
McKinney、Texas、アメリカ、75071
- Woodlands Medical Specialists, PA
-
Mesquite、Texas、アメリカ、75150
- Woodlands Medical Specialists, PA
-
Plano、Texas、アメリカ、75093
- Texas Oncology-Plano West
-
Plano、Texas、アメリカ、75075-7787
- Texas Oncology - Plano East
-
San Antonio、Texas、アメリカ、78229
- Mays Cancer Center
-
The Woodlands、Texas、アメリカ、77380
- US Oncology
-
Tyler、Texas、アメリカ、75702
- Texas Oncology - Tyler Cancer Center
-
-
Utah
-
Murray、Utah、アメリカ、84107
- Intermountain Medical Center
-
St. George、Utah、アメリカ、84790
- Intermountain Healthcare - St. George
-
-
Vermont
-
Burlington、Vermont、アメリカ、05401
- The University of Vermont Medical Center Inc.
-
-
Virginia
-
Winchester、Virginia、アメリカ、22601
- Shenandoah Oncology, P.C.
-
-
-
-
-
San Juan、アルゼンチン、5400
- CER San Juan
-
-
Buenos Air
-
Buenos Aires、Buenos Air、アルゼンチン、C1426ABP
- Fundación Respirar
-
Ciudad Autónoma de Buenos Aire、Buenos Air、アルゼンチン、C1027AAP
- Centro de Investigaciones Metabólicas (CINME)
-
-
Buenos Aires F.D.
-
CABA、Buenos Aires F.D.、アルゼンチン、1125
- Fundación Cenit Para La Investigación En Neurociencias
-
-
Córdoba Province
-
Río Cuarto、Córdoba Province、アルゼンチン、5800
- Instituto Médico Río Cuarto
-
-
Tucumán Province
-
San Miguel de Tucumán、Tucumán Province、アルゼンチン、4000
- Centro Medico San Roque
-
-
-
-
Central District
-
Kfar Saba、Central District、イスラエル、4428164
- Meir Medical Center
-
Petah Tikva、Central District、イスラエル
- Rabin Medical Center
-
Ramat Gan、Central District、イスラエル、5265601
- Sheba Medical Center
-
-
Jerusalem
-
Jerusalem、Jerusalem、イスラエル、9112001
- Hadassah Medical Center
-
-
Southern District
-
Beersheba、Southern District、イスラエル、8400000
- Soroka Medical Center
-
-
Tell Abīb
-
Tel Aviv、Tell Abīb、イスラエル、6423906
- Sourasky Medical Center
-
-
-
-
-
Bari、イタリア、70124
- Instituto Tumori Giovanni Paolo II
-
Grosseto、イタリア、58100
- Ospedale Misericordia di Grosseto
-
Milan、イタリア、20132
- Ospedale San Raffaele
-
Viterbo、イタリア、01100
- ASL Viterbo Ospedale Belcolle
-
-
Catania
-
Misterbianco、Catania、イタリア、95045
- Humanitas Istituto Clinico Catanese
-
-
Emilia-Romagna
-
Meldola、Emilia-Romagna、イタリア、47014
- IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
-
-
Friuli Venezia Giulia
-
Udine、Friuli Venezia Giulia、イタリア、33100
- P.O. "S. Maria della Misericordia" Azienda Sanitaria Universitaria Friuli Centrale
-
-
-
-
-
Thessaloniki、ギリシャ、546 45
- Euromedica General Clinic of Thessaloniki
-
-
Achaḯa
-
Pátrai、Achaḯa、ギリシャ、26504
- University Hospital of Patras
-
-
Attikí
-
Athens、Attikí、ギリシャ、115 28
- Alexandra Hospital
-
-
Irakleío
-
Heraklion、Irakleío、ギリシャ、711 10
- University General Hospital of Heraklion
-
-
-
-
Stockholms
-
Stockholm、Stockholms、スウェーデン、171 76
- Karolinska Universitetssjukhuset Solna
-
-
Örebro Län [se-18]
-
Örebro、Örebro Län [se-18]、スウェーデン、701 85
- Universitetssjukhuset Örebro
-
-
-
-
-
Badajoz、スペイン、06006
- Hospital Infanta Cristina
-
Madrid、スペイン、28009
- Hospital General Universitario Gregorio Marañon
-
Toledo、スペイン、45007
- Hospital Universitario de Toledo
-
-
A Coruña [La Coruña]
-
A Coruña、A Coruña [La Coruña]、スペイン、15006
- CHUAC-Hospital Teresa Herrera
-
-
Balears [Baleares]
-
Palma、Balears [Baleares]、スペイン、07120
- Hospital Universitari Son Espases
-
-
Barcelona [Barcelona]
-
Barcelona、Barcelona [Barcelona]、スペイン、08003
- Parc de Salut Mar - Hospital del Mar
-
-
Catalunya [Cataluña]
-
Barcelona、Catalunya [Cataluña]、スペイン、08036
- Hospital Clínic de Barcelona
-
-
Murcia, Región de
-
El Palmar、Murcia, Región de、スペイン、30120
- Hospital Clínico Universitario Virgen de la Arrixaca
-
-
Málaga
-
Málaga、Málaga、スペイン、29011
- H.R.U Málaga - Hospital Materno-infantil
-
-
Navarre
-
Pamplona、Navarre、スペイン、31009
- Complejo Hospitalario de Navarra
-
-
Tarragona [Tarragona]
-
Reus、Tarragona [Tarragona]、スペイン、43204
- Hospital Universitari Sant Joan de Reus
-
-
Valenciana, Comunitat
-
Valencia、Valenciana, Comunitat、スペイン、46017
- Hospital Universitario Doctor Peset
-
-
-
-
-
Hradec Králové、チェコ、500 05
- Fakultni nemocnice Hradec Kralove
-
-
Pardubice Region
-
Pardubice、Pardubice Region、チェコ、53203
- Multiscan
-
-
-
-
Capital Region
-
Copenhagen、Capital Region、デンマーク、2730
- Herlev and Gentofte Hospital
-
-
Central Jutland
-
Herning、Central Jutland、デンマーク、7400
- Regionshospitalet Gødstrup
-
-
-
-
-
Adana、トルコ(Türkiye)、01370
- Adana City Hospital
-
Ankara、トルコ(Türkiye)、06520
- Memorial Ankara Hastanesi
-
Ankara、トルコ(Türkiye)、06010
- Ankara Gülhane Eitim ve Aratrma Hastanesi
-
Diyarbakır、トルコ(Türkiye)、21200
- Dicle Üniversitesi
-
Edirne、トルコ(Türkiye)、22030
- Trakya University
-
Istanbul、トルコ(Türkiye)、34722
- TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
-
Malatya、トルコ(Türkiye)、44280
- İnönü Üniversitesi Turgut Özal Tıp Merkezi Eğitim ve Araştırma Hastanesi
-
-
Konya
-
Meram、Konya、トルコ(Türkiye)、42080
- Necmettin Erbakan Meram Medical Fac.
-
-
İzmir
-
Cordaleo、İzmir、トルコ(Türkiye)、009035575
- Izmir Medical Park Hospital
-
-
-
-
-
Budapest、ハンガリー、1122
- Országos Onkológiai Intézet
-
Budapest、ハンガリー、1062
- Magyar Honvedseg Egeszsegugyi Kozpont
-
-
Bács-Kiskun county
-
Kecskemét、Bács-Kiskun county、ハンガリー、6000
- Bacs-Kiskun Megyei Korhaz
-
-
Győr-Moson-Sopron
-
Győr、Győr-Moson-Sopron、ハンガリー、9024
- Petz Aladar Egyetemi Oktato Korhaz
-
-
-
-
Aquitaine
-
Bordeaux、Aquitaine、フランス、33076
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
-
-
Finistère
-
Brest、Finistère、フランス、29609
- CHRU de Brest
-
-
Loire-Atlantique
-
Nantes、Loire-Atlantique、フランス、44277
- Hôpital privé du Confluent SAS
-
-
Vendée
-
La Roche-sur-Yon、Vendée、フランス、85000
- CHD Vendee
-
-
-
-
-
Namur、ベルギー、5000
- CHU UCL Namur/Site Sainte Elisabeth
-
-
Antwerpen
-
Brasschaat、Antwerpen、ベルギー、2930
- Algemeen Ziekenhuis klina
-
-
Limburg
-
Hasselt、Limburg、ベルギー、3500
- Jessa Ziekenhuis
-
-
-
-
Masovian Voivodeship
-
Otwock、Masovian Voivodeship、ポーランド、05-400
- Europejskie Centrum Zdrowia - Oddzial Onkologii
-
-
Opole Voivodeship
-
Opole、Opole Voivodeship、ポーランド、45-060
- Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego
-
-
-
-
Estado de Baja California
-
Mexicali、Estado de Baja California、メキシコ、21200
- Centro de Investigacion en Artritis y Osteoporosis SC
-
Tijuana、Estado de Baja California、メキシコ、22010
- COI Tijuana - Centro Oncológico Internacional
-
-
Jalisco
-
Guadalajara、Jalisco、メキシコ、45647
- Centro Oncológico Internacional (COI)
-
-
Nuevo León
-
Monterrey、Nuevo León、メキシコ、64060
- Centro Regiomontano de Investigación
-
-
San Luis Potosí
-
San Luis Potosí City、San Luis Potosí、メキシコ、78209
- Oncologico Potosino, S.C.
-
-
-
-
-
Kaohsiung City、台湾、80756
- Kaohsiung Medical University Hospital
-
New Taipei City、台湾、231
- Taipei Tzu Chi General Hospital
-
Taipei、台湾、11217
- Taipei Veterans General Hospital
-
Taipei、台湾、10449
- Mackay Memorial Hospital
-
Taoyuan、台湾、333
- Chang Gung Medical Foundation-Linkou Branch
-
-
Tainan
-
Tainan、Tainan、台湾、71004
- Chi Mei Medical Center
-
-
-
-
Kyǒnggi-do
-
Seongnam、Kyǒnggi-do、韓国、13620
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [Seoul]
-
Seoul、Seoul-teukbyeolsi [Seoul]、韓国、02841
- Korea University Anam Hospital
-
Seoul、Seoul-teukbyeolsi [Seoul]、韓国、08308
- Korea University Guro Hospital
-
-
Taegu-Kwangyǒkshi
-
Daegu、Taegu-Kwangyǒkshi、韓国、41404
- Kyungpook National University Chilgok Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Have a diagnosis of HR+, HER2- locally advanced or metastatic breast cancer
-
Have radiologic evidence of disease progression or recurrence either
- On treatment with a CDK4/6 inhibitor with aromatase inhibitor (AI) as initial therapy for advanced disease, or
- On/after treatment with a CDK4/6 inhibitor plus endocrine therapy (ET) administered as adjuvant therapy for early stage breast cancer
-
Must be deemed appropriate for treatment with ET
-
If female, have a postmenopausal status by natural or surgical means or by ovarian function suppression
-
Have Response Evaluable Criteria in Solid Tumors (RECIST) evaluable disease (measurable disease and/or nonmeasurable disease)
-
Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale (Oken et al. 1982)
-
Have adequate renal, hematologic, and hepatic organ function
-
Must be able to swallow capsules/tablets
Exclusion Criteria:
- Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis
- Have symptomatic or untreated central nervous system metastasis
- Have received any systemic therapy between disease recurrence/progression and study screening
- Have received more than 1 line of therapy for advanced or metastatic disease.
- Have received prior chemotherapy for metastatic breast cancer (MBC)
- Have received prior treatment with fulvestrant, any investigational estrogen receptor (ER)-directed therapy (including selective ER degraders [SERDs] and non-SERDs), any phosphatidylinositol 3-kinase (PI3K)-, mammalian target of rapamycin (mTOR)-, or protein kinase B (AKT)-inhibitor
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm A: Abemaciclib plus Fulvestrant
Abemaciclib 150 milligram (mg) administered orally twice daily (BID) on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met. |
Administered orally. Administered IM. |
|
アクティブコンパレータ:Arm B: Placebo plus Fulvestrant
Placebo administered orally BID on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met. |
Administered IM. Administered orally. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival (PFS)
時間枠:Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
|
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. |
Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)
時間枠:Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
|
PFS is defined as the time from the date of randomization to the earliest date of disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first. |
Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
|
|
Objective Response Rate (ORR): Percentage of Participants Who Achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)
時間枠:Randomization until measured progressive disease (Up to 22 Months)
|
ORR is the best overall tumor response of CR or PR as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. |
Randomization until measured progressive disease (Up to 22 Months)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company
出版物と役立つリンク
一般刊行物
- Zapatero-Solana E, Ding Y, Pulliam N, de Dios A, Ortiz-Ruiz MJ, Lallena MJ. Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing. Int J Mol Sci. 2025 Mar 14;26(6):2643. doi: 10.3390/ijms26062643.
- Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Munoz M, Lai JI, Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. J Clin Oncol. 2025 Mar 20;43(9):1101-1112. doi: 10.1200/JCO-24-02086. Epub 2024 Dec 18.
- Kalinsky K, Wander SA, Hamilton E, Graff SL, Jeselsohn R, Park KH, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Ravenberg E, Amdur S, Litchfield LM, Bianchini G. Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy. Ann Oncol. 2026 Oct 24:S0923-7534(26)08075-0. doi: 10.1016/j.annonc.2026.10.1283. Online ahead of print.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 18238
- I3Y-MC-JPEF (その他の識別子:Eli Lilly and Company)
- 2021-002301-10 (EudraCT番号)
- 2023-506771-10-00 (その他の識別子:EU Trial Number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD 共有時間枠
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD 共有アクセス基準
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。